Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Chimeric gets FDA clearance, Cochlear posts record sales
News
Closing Bell: ASX gains over 0.5pc to reach new record high
News
Pot Stocks: Emyria and Cann split, but who will win the race to register their CBD product first?
Health & Biotech
ASX health stocks: dorsaVi leads the pack with 12% jump on major contract extension
News
Quarterlies Top 5: Cannabis, micro investing and cars top today’s list
Health & Biotech
ASX Health Stocks: Chimeric gets licence for CAR-T from U-Pen, Acrux gets nod from the FDA
Health & Biotech
‘Massive’ opportunity in psychedelic-based therapy, expert says
Health & Biotech
Weed Week: Amazon all-in on marijuana; free joints for jabs and Creso Pharma dual-listed in US
Health & Biotech
Why these 4 ASX cannabis stocks got investors’ attention today
News
Last Orders: ASX retreats following the budget; over fears of AAA credit rating loss & early rate hikes
News
Quarterlies Top 5: Here’s another online market place that’s rising today
Health & Biotech
Cann Group, Emyria team up in bid to gain TGA approval for low-dose CBD gelcap
News
IPO Watch: Two gold explorers lead a pack of ASX debuts in January
Health & Biotech
Cann Group just bought some exclusive access to Europe’s biggest medicinal cannabis market
IPO Watch
IPO Watch: ASX IPOs in 2020 up 42 per cent on average; here are the top performers
News
Rise and Shine: What you need to know before the ASX opens
IPO Watch